News coverage about TherapeuticsMD (NASDAQ:TXMD) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.9908954485922 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- TherapeuticsMD, Inc., (NASDAQ: TXMD) – Stock to Watch – Stock Watch (stocksnewstimes.com)
- One Most Risky Stock to Own In 2018: TherapeuticsMD, Inc. (TXMD) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Brokerages Expect TherapeuticsMD Inc (TXMD) to Post -$0.09 EPS (americanbankingnews.com)
- The 5 Most Shorted Nasdaq Stocks (msn.com)
- TherapeuticsMD (TXMD) Given “Buy” Rating at Noble Financial (americanbankingnews.com)
A number of brokerages recently commented on TXMD. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. BidaskClub lowered TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 31st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Oppenheimer reissued a “buy” rating and issued a $10.00 price objective on shares of TherapeuticsMD in a research note on Sunday, January 28th. Finally, Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. TherapeuticsMD has a consensus rating of “Buy” and an average price target of $14.50.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $4.66 million. During the same quarter last year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was down 8.0% compared to the same quarter last year. research analysts anticipate that TherapeuticsMD will post -0.38 earnings per share for the current year.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.